

Dominique de Valeriola

Dominique de Valeriola, MD, is the General Medical Director of the Institut Jules Bordet, as well as being Head of the Oncology Out-patient Unit. She is also associate professor in Oncology at the Université Libre de Bruxelles.

After spending two years at the University of Maryland Cancer Center (USA), she developed, as a researcher for the Belgian National Fund for Scientific Research (FNRS), an oncopharmacology lab at the Institut Jules Bordet and focused her research on the pharmacokinetics and pharmacodynamics of new anticancer drugs. This work was conducted in close collaboration with the Medical Oncology Unit.

Deeply involved in the day to day management of the clinical cancer research programme developed at the Institut Jules Bordet, she obtained a Master's degree in Management of Health and Care Institutions (MISS) at the Université Libre de Bruxelles in 1997.

Dr. de Valeriola is member of several scientific associations such as the American Association for Cancer Research (AACR) and the Belgian Society of Medical Oncology (BSMO).

Co-author of 56 scientific publications, she is actively involved in teaching medical students, oncologists and nurses at the Université Libre de Bruxelles. In 2006, she was asked to become advisor to the Belgian Ministry of Health in the oncology domain. Since then, Dr de Valeriola participated actively in the creation of the National Cancer Registry of which she is its Vice President. Furthermore, she was actively involved in the recognition of the medical oncology speciality, as well as in the agreement of breast clinics in Belgium. In March 2008, she was a key figure in the launching of the first Belgian National Cancer Plan.

She was named General Medical Director of the Jules Bordet Institute in 2001, and, since then, is pursuing her challenging ambition of promoting the comprehensive cancer centre to its highest level of excellence.

In September 2014, she was elected President of the Organisation of European Cancer Institutes (OECI), reinforcing her commitment and involvement in the organisation of oncology and in the promotion of quality cancer care and research throughout Europe.